These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 35269674)

  • 21. Reproductive and oncologic outcomes after progestin therapy for endometrial complex atypical hyperplasia or carcinoma.
    Kudesia R; Singer T; Caputo TA; Holcomb KM; Kligman I; Rosenwaks Z; Gupta D
    Am J Obstet Gynecol; 2014 Mar; 210(3):255.e1-4. PubMed ID: 24211482
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fertility-Sparing Treatment of Patients with Endometrial Cancer: A Review of the Literature.
    Leone Roberti Maggiore U; Khamisy-Farah R; Bragazzi NL; Bogani G; Martinelli F; Lopez S; Chiappa V; Signorelli M; Ditto A; Raspagliesi F
    J Clin Med; 2021 Oct; 10(20):. PubMed ID: 34682906
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The present status of metformin in fertility-preserving treatment in atypical endometrial hyperplasia and endometrioid endometrial cancer.
    Guan J; Chen XJ
    Front Endocrinol (Lausanne); 2022; 13():1041535. PubMed ID: 36387903
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fertility-Sparing Treatment for Atypical Endometrial Hyperplasia and Endometrial Cancer: A Cochrane Systematic Review Protocol.
    Fernandez-Montoli ME; Sabadell J; Contreras-Perez NA
    Adv Ther; 2021 May; 38(5):2717-2731. PubMed ID: 33830463
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Pregnant rate and pregnancy-relating factors of patients with early endometrial carcinoma and severe atypical hyperplasia of endometrium after fertility-preserving treatment by progestin].
    Cao DY; Yu M; Yang JX; Shen K; Huang HF; Cheng NH; Sun ZY; Deng CY; Yu Q; He FF
    Zhonghua Fu Chan Ke Za Zhi; 2013 Jul; 48(7):519-22. PubMed ID: 24284224
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Analysis of pregnancy-associated factors after fertility-sparing therapy in young women with early stage endometrial cancer or atypical endometrial hyperplasia.
    Fan Y; Li X; Wang J; Wang Y; Tian L; Wang J
    Reprod Biol Endocrinol; 2021 Aug; 19(1):118. PubMed ID: 34344384
    [TBL] [Abstract][Full Text] [Related]  

  • 27. National patterns of care and fertility outcomes for reproductive-aged women with endometrial cancer or atypical hyperplasia.
    Harrison RF; He W; Fu S; Zhao H; Sun CC; Suidan RS; Woodard TL; Rauh-Hain JA; Westin SN; Giordano SH; Meyer LA
    Am J Obstet Gynecol; 2019 Nov; 221(5):474.e1-474.e11. PubMed ID: 31128110
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Live births and maintenance with levonorgestrel IUD improve disease-free survival after fertility-sparing treatment of atypical hyperplasia and early endometrial cancer.
    Novikova OV; Nosov VB; Panov VA; Novikova EG; Krasnopolskaya KV; Andreeva YY; Shevchuk AS
    Gynecol Oncol; 2021 Apr; 161(1):152-159. PubMed ID: 33461741
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Should progesterone and estrogen receptors be assessed for predicting the response to conservative treatment of endometrial hyperplasia and cancer? A systematic review and meta-analysis.
    Raffone A; Travaglino A; Saccone G; Mollo A; De Placido G; Insabato L; Zullo F
    Acta Obstet Gynecol Scand; 2019 Aug; 98(8):976-987. PubMed ID: 30779338
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The combined GnRH-agonist and intrauterine levonorgestrel-releasing system treatment of complicated atypical hyperplasia and endometrial cancer: a pilot study.
    Pashov AI; Tskhay VB; Ionouchene SV
    Gynecol Endocrinol; 2012 Jul; 28(7):559-61. PubMed ID: 22296608
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [GnRH-a combined fertility-sparing re-treatment in women with endometrial carcinoma or atypical endomertial hyperplasia who failed to oral progestin therapy].
    Chen JY; Cao DY; Zhou HM; Yu M; Yang JX; Wang JH; Zhang Y; Cheng NH; Peng P
    Zhonghua Fu Chan Ke Za Zhi; 2021 Aug; 56(8):561-568. PubMed ID: 34420288
    [No Abstract]   [Full Text] [Related]  

  • 32. Fertility-Sparing Management Using Progestin for Young Women with Endometrial Cancer From a Population-Based Study.
    Kim SR; van der Zanden C; Ikiz H; Kuzelijevic B; Havelock J; Kwon JS
    J Obstet Gynaecol Can; 2018 Mar; 40(3):328-333. PubMed ID: 28986185
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic factors of oncological and reproductive outcomes in fertility-sparing treatment of complex atypical hyperplasia and low-grade endometrial cancer using oral progestin in Chinese patients.
    Zhou R; Yang Y; Lu Q; Wang J; Miao Y; Wang S; Wang Z; Zhao C; Wei L
    Gynecol Oncol; 2015 Dec; 139(3):424-8. PubMed ID: 26428941
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term outcomes of progestin plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer patients.
    Mitsuhashi A; Habu Y; Kobayashi T; Kawarai Y; Ishikawa H; Usui H; Shozu M
    J Gynecol Oncol; 2019 Nov; 30(6):e90. PubMed ID: 31576686
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Analysis of prognosis and pregnancy outcomes of fertility-preserving treatment for patients with stage Ⅰa, grade 2 endometrial cancer].
    Wang YQ; Zhou R; Xu LJ; Xia M; Lu Q; Liu GL; Shen DH; Wang G; He M; Wang JL
    Zhonghua Fu Chan Ke Za Zhi; 2020 May; 55(5):327-332. PubMed ID: 32464721
    [No Abstract]   [Full Text] [Related]  

  • 36. Oncologic and reproductive outcomes after fertility-sparing management with oral progestin for women with complex endometrial hyperplasia and endometrial cancer.
    Chen M; Jin Y; Li Y; Bi Y; Shan Y; Pan L
    Int J Gynaecol Obstet; 2016 Jan; 132(1):34-8. PubMed ID: 26493012
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and fertility outcomes of levonorgestrel-releasing intra-uterine system treatment for patients with atypical complex hyperplasia or endometrial cancer: a retrospective study.
    Leone Roberti Maggiore U; Martinelli F; Dondi G; Bogani G; Chiappa V; Evangelista MT; Liberale V; Ditto A; Ferrero S; Raspagliesi F
    J Gynecol Oncol; 2019 Jul; 30(4):e57. PubMed ID: 31074240
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Progestin therapy for obese women with complex atypical hyperplasia: levonorgestrel-releasing intrauterine device vs systemic therapy.
    Mandelbaum RS; Ciccone MA; Nusbaum DJ; Khoshchehreh M; Purswani H; Morocco EB; Smith MB; Matsuzaki S; Dancz CE; Ozel B; Roman LD; Paulson RJ; Matsuo K
    Am J Obstet Gynecol; 2020 Jul; 223(1):103.e1-103.e13. PubMed ID: 31978437
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Progestin plus metformin improves outcomes in patients with endometrial hyperplasia and early endometrial cancer more than progestin alone: a meta-analysis.
    Shao F; Li Y; Zhao Y
    Front Endocrinol (Lausanne); 2023; 14():1139858. PubMed ID: 37415671
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase II study of medroxyprogesterone acetate plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer.
    Mitsuhashi A; Sato Y; Kiyokawa T; Koshizaka M; Hanaoka H; Shozu M
    Ann Oncol; 2016 Feb; 27(2):262-6. PubMed ID: 26578736
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.